What could China's newly proposed foreign drug policy mean for multinational pharma companies, and how will it change the world’s second-largest pharma…

The FDA, which banned APIs coming from a Divi’s plant in India, has followed that with a warning letter that savages the facility for a lack of data integrity.

For nearly two years Teva struggled with impurity issues for an API manufactured at a plant in China.

Serum Institute of India CEO Adar Poonawalla struck a deal on Tuesday to pick up a defunct Czech outfit for €72 million.

Johnson & Johnson has kept a positive attitude about its blockbuster immunology drug Remicade and the biosimilar competition it’s facing.

Novartis' CEO said China's pharma market will surpass $300 billion by 2020, Hanmi failed to report olmutinib side effect on time, Celgene tapped…

The FDA issued Aurobindo Pharma a Form 483, citing six observations related to procedural improvements at the company’s Unit III facility at Bachupally in…

Swedish CDMO Recipharm’s growing global footprint in 2016 has positioned the company to take advantage of what is expected to be more consolidation and growth…

As large drugmakers face growth challenges in the U.S. and other developed countries with burdened healthcare budgets, China is looking more and more enticing.

Pharma Asia